Activated γδ T cells express the natural cytotoxicity receptor natural killer p44 and show cytotoxic activity against myeloma cellsM von Lilienfeld-Toal, Ingo Schmidt‐Wolf, Jacob Nattermann et al.|Clinical & Experimental Immunology|2006Cited by 90
Dexamethasone, High-Dose Cytarabine, and Cisplatin in Combination with Rituximab as Salvage Treatment for Patients with Relapsed or Refractory Aggressive Non-Hodgkin's LymphomaUlrich Mey, Ingo G.H. Schmidt‐Wolf, Andreas Neubauer et al.|Cancer Investigation|2006Cited by 61
Increase of In Vivo Antitumoral Activity by CD40L (CD154) Gene Transfer Into Pancreatic Tumor Cell-Dendritic Cell HybridsCarsten Ziske, Ingo G.H. Schmidt‐Wolf, Patricia E. Etzrodt et al.|Pancreas|2009Cited by 13
Anti-tumoral capabilities of effector cells after IFN-α or CpG-motif treatment of cocultured dendritic cellsMichael Erhardt, Marcus Gorschlüter, Ingo G.H. Schmidt‐Wolf et al.|Archivum Immunologiae et Therapiae Experimentalis|2006Cited by 8
A Phase II Trial of Dexamethasone, High-Dose Cytarabine, and Cisplatin (DHAP) in Combination with Rituximab as Salvage Treatment for Patients with Refractory or Relapsed Aggressive Non-Hodgkin’s Lymphoma.Ulrich Mey, Ingo G.H. Schmidt‐Wolf, John Strehl et al.|Blood|2004Cited by 3